Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Post-Infusion Monitoring Costs By Site of Care Among Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) Who Received Second-LINE Treatment with Lisocabtagene Maraleucel (LISO-CEL) in the Transform Study: A United States Subgr ...

Speaker(s)

McGarvey N1, Vaidya N1, Gitlin M1, Lee A1, Ung B2, Carattini T2, Keating SJ2
1BluePath Solutions, Los Angeles, CA, USA, 2Bristol Myers Squibb, Princeton, NJ, USA

Presentation Documents

OBJECTIVE: Although chimeric antigen receptor T cell therapy is generally administered in the inpatient setting, opportunities exist for treatment in the outpatient setting to reduce costs. Post-infusion costs for liso-cel by site of care may differ between the United States (US) and other countries. This analysis assessed post-infusion monitoring costs by site of care among US patients with LBCL treated with liso-cel as a second-line therapy in the TRANSFORM study (NCT03575351).

METHODS: Individual patient-level case report forms detailing health care resource utilization (HCRU) among patients receiving liso-cel were analyzed. A 2-step micro-costing methodology identified HCRU and estimated associated costs using a 6-month time horizon, beginning with the date of liso-cel infusion. First, HCRU in the 6-month timeframe post-infusion was calculated. Next, costs were applied to each HCRU. Unit costs were measured from the health care system perspective, using peer-reviewed literature and public sources, and adjusted to 2021 US dollars. Analyses were stratified by administration site.

RESULTS: Among 56 patients treated with liso-cel in TRANSFORM, 39 (70%) and 17 (30%) patients were classified as inpatients and outpatients, respectively. Estimated mean (median) 6-month total post-infusion monitoring costs (excluding liso-cel acquisition) were $96,436 ($67,169) and $51,823 ($42,172) for inpatients and outpatients, respectively, a difference of $44,613 ($24,997). Facility costs were the primary driver of costs in both settings. Among all patients, median (range) total length of stay (LOS) was shorter for outpatients than inpatients (0 [0‒21] vs 11 [0‒80] days). Among 8 (47%) outpatients who were hospitalized, median (range) time from liso-cel infusion to first inpatient admission was 18 (2‒160) days; median (range) total LOS was 9 (4‒21) days.

CONCLUSIONS: In US outpatients treated with liso-cel, lower costs and reduced LOS were observed when compared with inpatients. This study illustrates potential cost savings and reduced HCRU with outpatient administration of liso-cel in TRANSFORM.

Code

EE286

Topic

Economic Evaluation

Disease

Oncology